Sorry, you need to enable JavaScript to visit this website.

Chuck: When I was first diagnosed with polycythemia vera, the only treatment I had was phlebotomy. I got real low on iron, which was making me very sick.

Onscreen text: Chuck was diagnosed with polycythemia vera (PV) in 2014.

Tami: I was on regular chemo…called hydroxyurea. And the side effects were horrific. I had been going at this for almost four years at this point.

Onscreen text: Tami was diagnosed with high-risk myelofibrosis (MF) in 2015.

Onscreen text: THE PURPLE CHAIR

EPISODE 4: Reflecting on the Possibilities


Chuck: That's when I first started thinking about the possibility or the need for making a change.

Onscreen text: When you’re managing a rare, chronic blood cancer, it’s important to explore your options.

Chuck: The medication that the doctor said would be best for me was hydroxyurea. I wasn't real happy with it.

Onscreen text: Hydroxyurea, or HU, is a type of chemotherapy drug.

Donna: I was really fearful about that one word, chemotherapy. I'm a Southern girl, and I remember immediately worrying about my big hair.

Onscreen text: Donna was diagnosed with PV in 2020.

Mark: At one point, my doctor did talk about the possibility of me having a bone marrow transplant… And we’re just talking about options at that point. She said no, it’s not time.

Onscreen text: Mark was diagnosed with intermediate-risk MF in 2017.

Donna: The hydroxyurea, as we say in the south, made me take to the bed.

Tami: The chemo had not been effective for me. I was uncomfortable all the time...vomiting, diarrhea…

Donna: I just felt like I had the flu.

Chuck: For several years, I had the side effects of hydroxyurea, there was a stage where my spleen began to hurt…then we found out it was enlarged.


Tami: I had gone to see my doctor and I had said, we’ve got to do something.

Donna: I remember saying, I don't want to complain because I'm not a complainer. I can't do this for the rest of my life.

Chuck: I knew that it was important for me to not just trust the doctor, but to also advocate for myself about what was going on my body.

Donna: She said if you can't tolerate the hydroxyurea, we do have a medication that is promising.


Tami: He said it’s a different drug, and it’s called Jakafi.

Onscreen text: This is Tami's experience with Jakafi. Individual results may vary.

Onscreen text and narrator: Jakafi® (ruxolitinib) is the first FDA-approved prescription medicine for adults with PV who have already taken a medicine called hydroxyurea (HU) and it did not work well enough or they could not tolerate it. Jakafi is also the first FDA-approved prescription medicine for adults with intermediate or high-risk MF.

Onscreen text and narrator: Jakafi® (ruxolitinib) can cause serious side effects. Please see Important Safety Information in this video and see the Full Prescribing Information for Jakafi.

Chuck: When I started hearing positive things about Jakafi and that other patients were doing well with it, um, I said, well, maybe it’s time to make that change.

Donna: My doctor said, Donna, it is not a chemotherapy.

Onscreen text: Jakafi is not chemotherapy. It is a targeted treatment that works to help keep the production of blood cells under control.

Donna: She said there's a program called IncyteCARES that'll likely help you with affording the medication.

Onscreen text: IncyteCARES for Jakafi is a patient support program helping eligible patients with access and support.

Tami: This was the very first time I'd ever seen the name Incyte. And that was a perfect name because it gave me insight into what I was dealing with.


Mark: By the sixth month my levels were exactly where somebody who didn't have MF would be.

Mark: Three years in, I feel great. My symptoms are normal, as if I don't have MF. And my spleen is normal.

Onscreen text: This is Mark's experience with Jakafi. Individual results may vary. Mark has been taking Jakafi for intermediate-risk MF since 2017.

Chuck: When I went on Jakafi my spleen was about one point five its normal size, which is a little bit dangerous and painful. Since I’ve been on Jakafi, it’s back to where it needed to be.

Chuck: I've gone about 14 months without having to have a phlebotomy. My numbers are under control, um they've been consistent for well over a year now.

Onscreen text: This is Chuck's experience with Jakafi. Individual results may vary. Chuck has been taking Jakafi for PV since 2020.

Donna: Since I've been on Jakafi, my levels are still great.

Donna: Jakafi is really doing what it's intended to do, just decrease the production of the red blood cells. My white blood counts are within normal limits.

Onscreen text: This is Donna’s experience with Jakafi. Individual results may vary. Donna has been taking Jakafi for PV since 2020.

Tami: We played with the dosage for a little while, but after we worked through that I started to feel like a human being again. I wasn't sick all the time. I wasn't lethargic. I wasn't itching all the time. I wasn't waking up drenched in sweat. I wasn't having the headaches anymore.

Onscreen text: Your Healthcare Professional will determine the appropriate dose of Jakafi for you. This is Tami's experience with Jakafi. Individual results may vary. Tami has been taking Jakafi for high-risk MF since 2015.

Tami: My MF is now under my control—mine and Jakafi's.

Onscreen text and narrator: How your PV or MF may respond to Jakafi depends on your specific circumstances. Individual results may vary. Talk to your Healthcare Professional to see if Jakafi may be right for you.


Donna: There's a lot of people that feel kind of hopeless when they've been given, um, this diagnosis, but for me, Jakafi gave me more hope.

Mark: Taking this medicine has, has changed me because I'm not afraid to, to talk about it. And you know, you have to communicate. That's the only way you can, can stay on top of this.

Donna: I don't know what the blessing is really going to be from this diagnosis, but maybe it's to help other people some way.

Mark: … And that's probably why I'm sitting here now.

Onscreen text: NEXT EPISODE

We Are Not Alone

Onscreen text: Brought to you by Jakafi® (ruxolitinib)


Onscreen text and narrator: Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information at, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.

Onscreen text: LEARN MORE ABOUT JAKAFI® (ruxolitinib)


This video is sponsored by Incyte Corporation. Jakafi and the Jakafi logo are registered trademarks of Incyte.

© 2022, Incyte Corporation. MAT-JAK-02977  03/22


Reflecting on the Possibilities

How did exploring their treatment possibilities change their perspectives? The patients look back on the specific steps that led them to discover their individual paths to possible.

We’re Saving a Seat, Just for You

Your story could help educate and inspire others. Learn how you can join a growing network of Incyte Mentors by becoming an Ambassador for Jakafi.